385 related articles for article (PubMed ID: 17853313)
1. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
[TBL] [Abstract][Full Text] [Related]
2. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
3. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH
Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study.
Di Lorenzo G; Di Trolio R; Montesarchio V; Palmieri G; Nappa P; Delfino M; De Placido S; Dezube BJ
Cancer; 2008 Mar; 112(5):1147-52. PubMed ID: 18098221
[TBL] [Abstract][Full Text] [Related]
6. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities.
Potouridou I; Korfitis C; Ioannidou D; Polydorou D; Zakopoulou N; Stratigos AJ; Katsambas AD
Br J Dermatol; 2008 Feb; 158(2):431-2. PubMed ID: 18067475
[No Abstract] [Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
Amantea MA; Forrest A; Northfelt DW; Mamelok R
Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
[TBL] [Abstract][Full Text] [Related]
8. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
[TBL] [Abstract][Full Text] [Related]
10. Penile ulceration during pegylated doxorubicin chemotherapy of classical Kaposi's sarcoma.
Cannavò SP; Borgia F; Scimone A; Guarneri B
Acta Derm Venereol; 2009; 89(2):216-7. PubMed ID: 19326025
[No Abstract] [Full Text] [Related]
11. Successful treatment of an HIV-positive patient with unmasking Kaposi's sarcoma immune reconstitution inflammatory syndrome.
Speicher DJ; Sehu MM; Johnson NW; Shaw DR
J Clin Virol; 2013 Jul; 57(3):282-5. PubMed ID: 23578530
[TBL] [Abstract][Full Text] [Related]
12. Triple secondary neoplasms: penis, lip and oral cavity in an AIDS patient treated with pegylated liposomal doxorubicin for cutaneous Kaposi's sarcoma.
Volkow P; Lizano M; Carrillo-García A; Pérez-Montiel D; Garciadiego P
AIDS; 2014 Sep; 28(15):2327-9. PubMed ID: 25313589
[No Abstract] [Full Text] [Related]
13. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment.
Guenova E; Metzler G; Hoetzenecker W; Berneburg M; Rocken M
Arch Dermatol; 2008 May; 144(5):692-3. PubMed ID: 18490609
[No Abstract] [Full Text] [Related]
14. Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study.
Dalu D; Fasola C; Ammoni L; De Francesco D; Cona MS; Rota S; Ferrario S; Gambaro A; Tosca N; Piva S; La Verde N
J Chemother; 2021 Sep; 33(5):342-347. PubMed ID: 34060438
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
Duggan ST; Keating GM
Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391
[TBL] [Abstract][Full Text] [Related]
16. Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment.
Dezube BJ
Expert Rev Anticancer Ther; 2002 Apr; 2(2):193-200. PubMed ID: 12113241
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Pegylated Liposomal Doxorubicin-Based Chemotherapy of AIDS-Related Kaposi's Sarcoma: A Meta-Analysis.
Liu R; Zhou J; Yang S; Zhang Z
Am J Ther; 2018; 25(6):e719-e721. PubMed ID: 29509553
[No Abstract] [Full Text] [Related]
18. Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review.
Di Trolio R; Di Lorenzo G; Delfino M; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(2):253-63. PubMed ID: 16831292
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
20. Bilateral eyelid Kaposi's sarcoma in an HIV-negative patient.
Fernández-Montalvo L; Ibáñez-Flores N; Cifuentes-Canorea P; Castellar-Cerpa J; Graell-Martín X; Cuadrado-Claramonte V
Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):606-609. PubMed ID: 30055902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]